May 2026Platinum re-challenge in platinum-resistant ovarian cancer: real-world patterns and outcomesOvarian cancer
April 2026Assessing the cumulative effect of high-risk factors for disease progression and death on real-world progression-free survival (rwPFS) in patients with advanced ovarian cancer (aOC)Ovarian cancer
December 2025Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS)Comparative effectivenessOvarian cancerReal-World Data
May 2025The BEV1L study: do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?Comparative effectivenessOvarian cancerReal-World DataTreatment and Testing patterns
January 2025Niraparib as first-line maintenance therapy in patients with stage III ovarian cancer and no visible residual disease: AR1ZE real-world studyOvarian cancer
May 2024The BEV1L study: do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?Ovarian cancer
May 2023Effectiveness of PARP inhibitor maintenance therapy in advanced ovarian cancer by BRCA1/2 and HRD signature in real-world practiceComparative effectivenessOvarian cancerClinical development